Hualan Biological Vaccine Inc. (SHE:301207)
China · Delayed Price · Currency is CNY 19.17
+0.55 (2.95%)
At close: Mar 27, 2026
Hualan Biological Vaccine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,203 | 1,126 | 2,409 | 1,824 | 1,830 |
Other Revenue | - | 1.83 | 1.2 | 1.57 | - |
| 1,203 | 1,128 | 2,410 | 1,826 | 1,830 | |
Revenue Growth (YoY) | 6.62% | -53.21% | 32.03% | -0.23% | -24.59% |
Cost of Revenue | 266.94 | 286.78 | 382.02 | 369.19 | 354.01 |
Gross Profit | 935.56 | 841.03 | 2,028 | 1,456 | 1,476 |
Selling, General & Admin | 594.8 | 582.54 | 1,019 | 776.35 | 647.5 |
Research & Development | 151.3 | 162.64 | 91.11 | 134.64 | 144.13 |
Other Operating Expenses | 1.86 | 10.61 | 15.18 | 12.59 | 10.84 |
Operating Expenses | 778.68 | 746.39 | 1,146 | 952.36 | 803.51 |
Operating Income | 156.89 | 94.64 | 881.98 | 504.09 | 672.29 |
Interest Expense | 2.55 | -6.1 | -6.08 | -10.69 | -13.32 |
Interest & Investment Income | 81.25 | 89.29 | 81.93 | 72.01 | 28.82 |
Currency Exchange Gain (Loss) | - | 0.06 | -0.23 | -0.11 | 0.25 |
Other Non Operating Income (Expenses) | -7.22 | -0.08 | -0.15 | 0.08 | -0.19 |
EBT Excluding Unusual Items | 233.47 | 177.81 | 957.44 | 565.37 | 687.85 |
Gain (Loss) on Sale of Investments | 12.73 | 24.3 | 39.68 | 16.85 | 14.25 |
Gain (Loss) on Sale of Assets | -0.2 | -0.14 | -0.2 | 0.63 | - |
Asset Writedown | -58.21 | -0.24 | -0.25 | -0.05 | -1 |
Other Unusual Items | - | 12.82 | 10.21 | 6.68 | 4.65 |
Pretax Income | 187.79 | 214.55 | 1,007 | 589.48 | 705.75 |
Income Tax Expense | 4.87 | 9.03 | 146.91 | 69.84 | 84.78 |
Net Income | 182.92 | 205.52 | 859.97 | 519.63 | 620.97 |
Net Income to Common | 182.92 | 205.52 | 859.97 | 519.63 | 620.97 |
Net Income Growth | -11.00% | -76.10% | 65.50% | -16.32% | -32.86% |
Shares Outstanding (Basic) | 595 | 598 | 601 | 590 | 540 |
Shares Outstanding (Diluted) | 595 | 598 | 602 | 590 | 540 |
Shares Change (YoY) | -0.51% | -0.71% | 2.03% | 9.33% | 0.01% |
EPS (Basic) | 0.31 | 0.34 | 1.43 | 0.88 | 1.15 |
EPS (Diluted) | 0.31 | 0.34 | 1.43 | 0.88 | 1.15 |
EPS Growth | -10.54% | -75.93% | 62.20% | -23.46% | -32.86% |
Free Cash Flow | 347.43 | 416.45 | 825.42 | 196.01 | -66.73 |
Free Cash Flow Per Share | 0.58 | 0.70 | 1.37 | 0.33 | -0.12 |
Dividend Per Share | - | 0.200 | 0.600 | 0.200 | 0.133 |
Dividend Growth | - | -66.67% | 200.00% | 50.04% | - |
Gross Margin | 77.80% | 74.57% | 84.15% | 79.78% | 80.65% |
Operating Margin | 13.05% | 8.39% | 36.59% | 27.61% | 36.74% |
Profit Margin | 15.21% | 18.22% | 35.68% | 28.46% | 33.94% |
Free Cash Flow Margin | 28.89% | 36.93% | 34.24% | 10.74% | -3.65% |
EBITDA | 298.11 | 235 | 1,022 | 638.51 | 740.2 |
EBITDA Margin | 24.79% | 20.84% | 42.41% | 34.98% | 40.45% |
D&A For EBITDA | 141.22 | 140.37 | 140.33 | 134.42 | 67.91 |
EBIT | 156.89 | 94.64 | 881.98 | 504.09 | 672.29 |
EBIT Margin | 13.05% | 8.39% | 36.59% | 27.61% | 36.74% |
Effective Tax Rate | 2.59% | 4.21% | 14.59% | 11.85% | 12.01% |
Revenue as Reported | 1,203 | 1,128 | 2,410 | 1,826 | 1,830 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.